Search

Your search keyword '"Van Veldhuisen, Dirk J"' showing total 4,025 results
Start Over Author "Van Veldhuisen, Dirk J"
4,025 results on '"Van Veldhuisen, Dirk J"'

5. Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF

Author

Dewan, Pooja, Shen, Li, Pedro Ferreira, João, Jhund, Pardeep S., Anand, Inder S., Chandra, Alvin, Chiang, Lu-May, Claggett, Brian, Desai, Akshay S., Gong, Jianjian, Lam, Carolyn S.P., Lefkowitz, Martin P., Maggioni, Aldo P., Martinez, Felipe, Packer, Milton, Redfield, Margaret M., Rouleau, Jean L., van Veldhuisen, Dirk J., Zannad, Faiez, Zile, Michael R., Solomon, Scott D., and McMurray, John J.V.

Published
2024
Full Text
View/download PDF

6. 2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF II

Author

Gustafsson, Finn, Petrie, Mark C., Komtebedde, Jan, Swarup, Vijendra, Winkler, Sebastian, Hasenfuß, Gerd, Borlaug, Barry A., Mohan, Rajeev C., Flaherty, James D., Sverdlov, Aaron L., Fail, Peter S., Chung, Eugene S., Lurz, Philipp, Lilly, Scott, Kaye, David M., Cleland, John G.F., Cikes, Maja, Leon, Martin B., Cutlip, Donald E., van Veldhuisen, Dirk J., Solomon, Scott D., and Shah, Sanjiv J.

Published
2024
Full Text
View/download PDF

7. Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure

Author

de Koning, Marie-Sophie L. Y., Emmens, Johanna E., Romero-Hernández, Esteban, Bourgonje, Arno R., Assa, Solmaz, Figarska, Sylwia M., Cleland, John G. F., Samani, Nilesh J., Ng, Leong L., Lang, Chim C., Metra, Marco, Filippatos, Gerasimos S., van Veldhuisen, Dirk J., Anker, Stefan D., Dickstein, Kenneth, Voors, Adriaan A., Lipsic, Erik, van Goor, Harry, and van der Harst, Pim

Published
2023
Full Text
View/download PDF

12. Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction

Author

Girerd, Nicolas, Cleland, John, Anker, Stefan D, Byra, William, Lam, Carolyn SP, Lapolice, David, Mehra, Mandeep R, van Veldhuisen, Dirk J, Bresso, Emmanuel, Lamiral, Zohra, Greenberg, Barry, and Zannad, Faiez

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Trials and Supportive Activities, Cardiovascular, Clinical Research, Heart Disease, Heart Disease - Coronary Heart Disease, Atrial Remodeling, Biomarkers, Case-Control Studies, Coronary Artery Disease, Death, Sudden, Cardiac, Growth Differentiation Factor 15, Heart Failure, Humans, Inflammation, Myocardial Infarction, Natriuretic Peptide, Brain, Peptide Fragments, Proteomics, Stroke, Stroke Volume, Ventricular Dysfunction, Left
Abstract

Patients with heart failure (HF) and coronary artery disease (CAD) have a high risk for cardiovascular (CV) events including HF hospitalization, stroke, myocardial infarction (MI) and sudden cardiac death (SCD). The present study evaluated associations of proteomic biomarkers with CV outcome in patients with CAD and HF with reduced ejection fraction (HFrEF), shortly after a worsening HF episode. We performed a case-control study within the COMMANDER HF international, double-blind, randomized placebo-controlled trial investigating the effects of the factor-Xa inhibitor rivaroxaban. Patients with the following first clinical events: HF hospitalization, SCD and the composite of MI or stroke were matched with corresponding controls for age, sex and study drug. Plasma concentrations of 276 proteins with known associations with CV and cardiometabolic mechanisms were analyzed. Results were corrected for multiple testing using false discovery rate (FDR). In 485 cases and 455 controls, 49 proteins were significantly associated with clinical events of which seven had an adjusted FDR  0.20). When adding the biomarkers significantly associated with the above outcome to a clinical model (including NT-proBNP), the C-index increase was 0.057 (0.033-0.082), p

Published
2022

16. Atrial Fibrillation Burden and Atrial Shunt Therapy in Heart Failure With Preserved Ejection Fraction

Author

Patel, Ravi B., Reddy, Vivek Y., Komtebedde, Jan, Wegerich, Stephan W., Sekaric, Jadranka, Swarup, Vijay, Walton, Antony, Laurent, Gabriel, Chetcuti, Stanley, Rademann, Matthias, Bergmann, Martin, McKenzie, Scott, Bugger, Heiko, Bruno, Raphael Romano, Herrmann, Howard C., Nair, Ajith, Gupta, Deepak K., Lim, Scott, Kapadia, Samir, Gordon, Robert, Vanderheyden, Marc, Noel, Thomas, Bailey, Steven, Gertz, Zachary M., Trochu, Jean-Noël, Cutlip, Donald E., Leon, Martin B., Solomon, Scott D., van Veldhuisen, Dirk J., Auricchio, Angelo, and Shah, Sanjiv J.

Published
2023
Full Text
View/download PDF

18. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Author

Anker, Stefan D, Butler, Javed, Khan, Muhammad Shahzeb, Abraham, William T, Bauersachs, Johann, Bocchi, Edimar, Bozkurt, Biykem, Braunwald, Eugene, Chopra, Vijay K, Cleland, John G, Ezekowitz, Justin, Filippatos, Gerasimos, Friede, Tim, Hernandez, Adrian F, Lam, Carolyn SP, Lindenfeld, JoAnn, McMurray, John JV, Mehra, Mandeep, Metra, Marco, Packer, Milton, Pieske, Burkert, Pocock, Stuart J, Ponikowski, Piotr, Rosano, Giuseppe MC, Teerlink, John R, Tsutsui, Hiroyuki, Van Veldhuisen, Dirk J, Verma, Subodh, Voors, Adriaan A, Wittes, Janet, Zannad, Faiez, Zhang, Jian, Seferovic, Petar, and Coats, Andrew JS

Subjects
Clinical Research, Patient Safety, Clinical Trials and Supportive Activities, Cardiovascular, Heart Disease, Prevention, Good Health and Well Being, Betacoronavirus, COVID-19, Clinical Trials as Topic, Coronavirus Infections, Europe, Heart Failure, Humans, Informed Consent, Pandemics, Patient Selection, Pneumonia, Viral, Research Design, SARS-CoV-2, Heart failure, Clinical trials, Coronavirus, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has important implications for the safety of participants in clinical trials and the research staff caring for them and, consequently, for the trials themselves. Patients with heart failure may be at greater risk of infection with COVID-19 and the consequences might also be more serious, but they are also at risk of adverse outcomes if their clinical care is compromised. As physicians and clinical trialists, it is our responsibility to ensure safe and effective care is delivered to trial participants without affecting the integrity of the trial. The social contract with our patients demands no less. Many regulatory authorities from different world regions have issued guidance statements regarding the conduct of clinical trials during this COVID-19 crisis. However, international trials may benefit from expert guidance from a global panel of experts to supplement local advice and regulations, thereby enhancing the safety of participants and the integrity of the trial. Accordingly, the Heart Failure Association of the European Society of Cardiology on 21 and 22 March 2020 conducted web-based meetings with expert clinical trialists in Europe, North America, South America, Australia, and Asia. The main objectives of this Expert Position Paper are to highlight the challenges that this pandemic poses for the conduct of clinical trials in heart failure and to offer advice on how they might be overcome, with some practical examples. While this panel of experts are focused on heart failure clinical trials, these discussions and recommendations may apply to clinical trials in other therapeutic areas.

Published
2020

19. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial

Author

Mehra, Mandeep R, Vaduganathan, Muthiah, Fu, Min, Ferreira, João Pedro, Anker, Stefan D, Cleland, John GF, Lam, Carolyn SP, van Veldhuisen, Dirk J, Byra, William M, Spiro, Theodore E, Deng, Hsiaowei, Zannad, Faiez, and Greenberg, Barry

Subjects
Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Clinical Research, Brain Disorders, Neurosciences, Stroke, Clinical Trials and Supportive Activities, Heart Disease, Cardiovascular, Heart Disease - Coronary Heart Disease, Patient Safety, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Brain Ischemia, Case-Control Studies, Coronary Artery Disease, Double-Blind Method, Drug Therapy, Combination, Factor Xa Inhibitors, Female, Heart Failure, Hemorrhage, Humans, Incidence, Ischemic Attack, Transient, Male, Middle Aged, Myocardial Infarction, Placebos, Platelet Aggregation Inhibitors, Rivaroxaban, Stroke Volume, Heart failure, Oral anticoagulation, Thrombotic, Transient ischaemic attack, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences
Abstract

AimsStroke is often a devastating event among patients with heart failure with reduced ejection (HFrEF). In COMMANDER HF, rivaroxaban 2.5 mg b.i.d. did not reduce the composite of first occurrence of death, stroke, or myocardial infarction compared with placebo in patients with HFrEF, coronary artery disease (CAD), and sinus rhythm. We now examine the incidence, timing, type, severity, and predictors of stroke or a transient ischaemic attack (TIA), and seek to establish the net clinical benefit of treatment with low-dose rivaroxaban.Methods and resultsIn this double-blind, randomized trial, 5022 patients who had HFrEF(≤40%), elevated natriuretic peptides, CAD, and who were in sinus rhythm were treated with rivaroxaban 2.5 mg b.i.d. or placebo in addition to antiplatelet therapy, after an episode of worsening HF. The primary neurological outcome for this post hoc analysis was time to first event of any stroke or TIA. Over a median follow-up of 20.5 (25th-75th percentiles 20.0-20.9) months, 150 all-cause stroke (127) or TIA (23) events occurred (ischaemic stroke in 82% and haemorrhagic stroke in 11% of stroke events). Overall, 47.5% of first-time strokes were either disabling (16.5%) or fatal (31%). Prior stroke, low body mass index, geographic region, and the CHA2DS2-VASc score were predictors of stroke/TIA. Rivaroxaban significantly reduced the primary neurological endpoint of all-cause stroke or TIA compared with placebo by 32% (1.29 events vs. 1.90 events per 100 patient-years), adjusted for the time from index HF event to randomization and stratified by geographic region (adjusted hazard ratio 0.68, 95% confidence interval 0.49-0.94), with a number needed to treat of 164 patients per year to prevent one stroke/TIA event. The principal safety endpoint of fatal bleeding or bleeding into a critical space, occurred at a similar rate on rivaroxaban and placebo (0.44 events vs. 0.55 events per 100 patient-years).ConclusionsPatients with HFrEF and CAD are at risk for stroke or TIA in the period following an episode of worsening heart failure in the absence of atrial fibrillation. Most strokes are of ischaemic origin and nearly half are either disabling or fatal. Rivaroxaban at a dose of 2.5 mg b.i.d. reduced rates of stroke or TIA compared with placebo in this population.Trial registrationCOMMANDER HF (A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure); ClinicalTrials.gov NCT01877915.

Published
2019

20. Galectin-3, Acute Kidney Injury and Myocardial Damage in Patients With Acute Heart Failure

Author

HORIUCHI, YU, WETTERSTEN, NICHOLAS, VAN VELDHUISEN, DIRK J., MUELLER, CHRISTIAN, FILIPPATOS, GERASIMOS, NOWAK, RICHARD, HOGAN, CHRISTOPHER, KONTOS, MICHAEL C., CANNON, CHAD M., MÜELLER, GERHARD A., BIRKHAHN, ROBERT, TAUB, PAM, VILKE, GARY M., MCDONALD, KENNETH, MAHON, NIALL, NUÑEZ, JULIO, BRIGUORI, CARLO, PASSINO, CLAUDIO, DUFF, STEPHEN, MAISEL, ALAN, and MURRAY, PATRICK T.

Published
2023
Full Text
View/download PDF

25. Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction

Author

Patel, Ravi B., primary, Silvestry, Frank E., additional, Komtebedde, Jan, additional, Solomon, Scott D., additional, Hasenfuß, Gerd, additional, Litwin, Sheldon E., additional, Borlaug, Barry A., additional, Price, Matthew J., additional, Kawash, Rami, additional, Hummel, Scott L., additional, Cutlip, Donald E., additional, Leon, Martin B., additional, van Veldhuisen, Dirk J., additional, Rieth, Andreas J., additional, McKenzie, Scott, additional, Bugger, Heiko, additional, Mazurek, Jeremy A., additional, Kapadia, Samir R., additional, Vanderheyden, Marc, additional, Ky, Bonnie, additional, and Shah, Sanjiv J., additional

Published
2024
Full Text
View/download PDF

26. Heart failure with normal LVEF in BIOSTAT-CHF

Author

Baumhove, Lukas, Tromp, Jasper, Figarska, Sylwia, van Essen, Bart J., Anker, Stefan D., Dickstein, Kenneth, Cleland, John G., Lang, Chim C., Filippatos, Gerasimos, Ng, Leong L., Samani, Nilesh J., Metra, Marco, van Veldhuisen, Dirk J., Lam, Carolyn S.P., Voors, Adriaan A., and van der Meer, Peter

Published
2022
Full Text
View/download PDF

27. Type D personality as a risk factor for adverse outcome in patients with cardiovascular disease: an individual patient data meta-analysis

Author

Lodder, Paul, Wicherts, Jelte M., Antens, Marijn, Albus, Christian, Bessonov, Ivan S., Condén, Emelie, Dulfer, Karolijn, Gostoli, Sara, Grande, Gesine, Hedberg, Pär, Herrmann-Lingen, Christoph, Jaarsma, Tiny, Koo, Malcolm, Lin, Ping, Lin, Tin-Kwang, Meyer, Thomas, Pushkarev, Georgiy, Rafanelli, Chiara, Raykh, Olga I., de Quadros, Alexandre Schaan, Schmidt, Marcia, Sumin, Alexei N., Utens, Elisabeth M.W.J., van Veldhuisen, Dirk J., Wang, Yini, and Kupper, Nina

Published
2023
Full Text
View/download PDF

28. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction

Author

Butt, Jawad H., Dewan, Pooja, Jhund, Pardeep S., Anand, Inder S., Atar, Dan, Ge, Junbo, Desai, Akshay S., Echeverria, Luis E., Køber, Lars, Lam, Carolyn S.P., Maggioni, Aldo P., Martinez, Felipe, Packer, Milton, Rouleau, Jean L., Sim, David, Van Veldhuisen, Dirk J., Vrtovec, Bojan, Zannad, Faiez, Zile, Michael R., Gong, Jianjian, Lefkowitz, Martin P., Rizkala, Adel R., Solomon, Scott D., and McMurray, John J.V.

Published
2022
Full Text
View/download PDF

31. Decongestion, kidney injury and prognosis in patients with acute heart failure

Author

Horiuchi, Yu, Wettersten, Nicholas, van Veldhuisen, Dirk J., Mueller, Christian, Filippatos, Gerasimos, Nowak, Richard, Hogan, Christopher, Kontos, Michael C., Cannon, Chad M., Müeller, Gerhard A., Birkhahn, Robert, Taub, Pam, Vilke, Gary M., Barnett, Olga, McDonald, Kenneth, Mahon, Niall, Nuñez, Julio, Briguori, Carlo, Passino, Claudio, Duff, Stephen, Maisel, Alan, and Murray, Patrick T.

Published
2022
Full Text
View/download PDF

35. Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction:Results of the Amylo-VIP-HF study

Author

Tubben, Alwin, Tingen, Hendrea S. A., Prakken, Niek H. J., van Empel, Vanessa P. M., Gorter, Thomas M., Meems, Laura M. G., Manintveld, Olivier C., Rienstra, Michiel, Tieleman, Robert G., Glaudemans, Andor W. J. M., van Veldhuisen, Dirk J., Slart, Riemer H. J. A., Nienhuis, Hans L. A., van der Meer, Peter, Tubben, Alwin, Tingen, Hendrea S. A., Prakken, Niek H. J., van Empel, Vanessa P. M., Gorter, Thomas M., Meems, Laura M. G., Manintveld, Olivier C., Rienstra, Michiel, Tieleman, Robert G., Glaudemans, Andor W. J. M., van Veldhuisen, Dirk J., Slart, Riemer H. J. A., Nienhuis, Hans L. A., and van der Meer, Peter

Published
2024

36. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial

Author

Akar, Joseph, Ando, Jiro, Anzai, Toshihisa, Asakura, Masanori, Bailey, Steven, Basuray, Anupam, Bauer, Fabrice, Bergmann, Martin, Blair, John, Cavendish, Jeffrey, Chung, Eugene, Cikes, Maja, Dauber, Ira, Donal, Erwan, Eicher, Jean-Christophe, Fail, Peter, Flaherty, James, Freixa, Xavier, Gafoor, Sameer, Gertz, Zachary, Gordon, Robert, Guazzi, Marco, Guerrero-Miranda, Cesar, Gupta, Deepak, Gustafsson, Finn, Hadadi, Cyrus, Hakemi, Emad, Handoko, Louis, Hass, Moritz, Hausleiter, Jorg, Hayward, Christopher, Hickey, Gavin, Hummel, Scott, Hussain, Imad, Isnard, Richard, Izumi, Chisato, Jondeau, Guillaume, Juneman, Elizabeth, Kinugawa, Koichiro, Kipperman, Robert, Krakowiak, Bartek, Krim, Selim, Larned, Joshua, Lewis, Gregory, Lipsic, Erik, Magalski, Anthony, Mazimba, Sula, Mazurek, Jeremy, McGrady, Michele, Mckenzie, Scott, Mehta, Shamir, Mignone, John, Morsli, Hakim, Nair, Ajith, Noel, Thomas, Orford, James, Parikh, Kishan, Patterson, Tiffany, Penicka, Martin, Petrie, Mark, Pieske, Burkert, Post, Martijn, Raake, Philip, Romero, Alicia, Ryan, John, Saito, Yoshihiko, Sakamoto, Takafumi, Sakata, Yasushi, Samara, Michael, Satya, Kumar, Sindone, Andrew, Starling, Randall, Trochu, Jean-Noël, Upadhya, Bharathi, van der Heyden, Jan, van Empel, Vanessa, Varma, Amit, Vest, Amanda, Wengenmayer, Tobias, Westenfeld, Ralf, Westermann, Dirk, Yamamoto, Kazuhiro, Zirlik, Andreas, Shah, Sanjiv J, Borlaug, Barry A, Chung, Eugene S, Cutlip, Donald E, Debonnaire, Philippe, Fail, Peter S, Gao, Qi, Hasenfuß, Gerd, Kahwash, Rami, Kaye, David M, Litwin, Sheldon E, Lurz, Philipp, Massaro, Joseph M, Mohan, Rajeev C, Ricciardi, Mark J, Solomon, Scott D, Sverdlov, Aaron L, Swarup, Vijendra, van Veldhuisen, Dirk J, Winkler, Sebastian, and Leon, Martin B

Published
2022
Full Text
View/download PDF

39. Dose-limiting, adverse event–associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial

Author

Abraham, William T., Piccini, Jonathan P., Dufton, Christopher, Carroll, Ian A., Healey, Jeffrey S., O’Connor, Christopher M., Marshall, Debra, Aleong, Ryan, van Veldhuisen, Dirk J., Rienstra, Michiel, Wilton, Stephen B., White, Michel, Sauer, William H., Anand, Inder S., Huebler, Sophia P., Connolly, Stuart J., and Bristow, Michael R.

Published
2022
Full Text
View/download PDF

41. Rationale and Design of the Groningen Intervention Study for the Preservation of Cardiac Function with Sodium Thiosulfate after St-segment Elevation Myocardial Infarction (GIPS-IV) trial

Author

de Koning, Marie-Sophie LY, van Dorp, Paulien, Assa, Solmaz, Hartman, Minke HT, Voskuil, Michiel, Anthonio, Rutger L, Veen, Duco, Pundziute-Do Prado, Gabija, Leiner, Tim, van Goor, Harry, van der Meer, Peter, van Veldhuisen, Dirk J, Nijveldt, Robin, Lipsic, Erik, and van der Harst, Pim

Published
2022
Full Text
View/download PDF

43. Serum Calcification Propensity Is Increased in Myocardial Infarction and Hints at a Pathophysiological Role Independent of Classical Cardiovascular Risk Factors.

Author

Mencke, Rik, Al Ali, Lawien, de Koning, Marie-Sophie L. Y., Pasch, Andreas, Minnion, Magdalena, Feelisch, Martin, van Veldhuisen, Dirk J., van der Horst, Iwan C. C., Gansevoort, Ron T., Bakker, Stephan J. L., de Borst, Martin H., van Goor, Harry, van der Harst, Pim, Lipsic, Erik, and Hillebrands, Jan-Luuk

Published
2024
Full Text
View/download PDF

46. Prevalence of wild‐type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo‐VIP‐HF study

Author

Tubben, Alwin, primary, Tingen, Hendrea S.A., additional, Prakken, Niek H.J., additional, van Empel, Vanessa P.M., additional, Gorter, Thomas M., additional, Meems, Laura M.G., additional, Manintveld, Olivier C., additional, Rienstra, Michiel, additional, Tieleman, Robert G., additional, Glaudemans, Andor W.J.M., additional, van Veldhuisen, Dirk J., additional, Slart, Riemer H.J.A., additional, Nienhuis, Hans L.A., additional, and van der Meer, Peter, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results